scholarly journals Clinical Trial of <i>Medicinal Synthetic Aluminum-Magnesium Silicate</i> (Antivirt<sup>&reg;</sup>) on Viral Loads and CD4-Lymphocytes Counts of HIV/AIDS Patients

2016 ◽  
Vol 06 (02) ◽  
pp. 37-41 ◽  
Author(s):  
Maduike C. O. Ezeibe ◽  
Dahiru Aleeyu ◽  
Ijeoma J. Ogbonna ◽  
Ekenma Kalu
Keyword(s):  
Clinical Trial ◽  
Magnesium Silicate ◽  
Aids Patients ◽  
Viral Loads ◽  
Cd4 Lymphocytes ◽  
Hiv Aids

scholarly journals HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jiayi Chen ◽  
Yang Liu ◽  
Sijing Liu ◽  
Dan Yuan ◽  
Ling Su ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Immune Cell ◽  
Virologic Failure ◽  
Epidemiological Surveillance ◽  
Aids Patients ◽  
Viral Loads ◽  
Art Program ◽  
And Control ◽  
Hiv 1 ◽  
Hiv Aids

The National Free Antiretroviral Therapy (ART) Program in China has initiated to provide ART to HIV-1 patients, which has acted as an efficient method to suppress viral replication and helps prevent onward transmissions. But the problems of HIV drug resistance (HIVDR) may also come along. There is little data on the prevalence of HIVDR in Chengdu, where the number of HIV/AIDS patients ranks first among provincial capitals. Therefore, epidemiological surveillance was conducted in this area. From 2014 to 2016, HIV/AIDS patients (15 years and older) who had received first-line ART for at least six months were enrolled. Demographic, behavioral information and medical history were recorded, and blood samples were collected for viral loads and immune cell count analyses. HIV-1 pol was obtained for HIV-1 subtypes and drug resistance-associated mutations (DRMs) among virologic failure patients. A total of 13,782 individuals were enrolled, and 481 samples were sequenced for subtypes and drug resistance analysis. Six subtypes were identified, among which CRF01_AE (54.3%) and CRF07_BC (41.6%) were the dominant subtypes, and CRF55_01B (0.4%) was detected in Chengdu for the first time. The prevalence of HIVDR in treatment-experienced patients was 1.8%, with 1.2% to nucleoside reverse transcriptase inhibitors (NRTIs), 1.7% to non-NRTIs (NNRTIs), and 0.14% to protease inhibitors (PIs). The leading DRMs observed in the study were M184I/V (59.59%) against NRTIs and K103N (37.55%) against NNRTIs. This study focused on the HIVDR surveillance among patients receiving treatment in Chengdu. The overall prevalence of HIVDR was relatively low among treated patients. These findings were believed to be contributed to an understanding of HIV-1 subtypes, HIVDR prevalence, and DRMs in Chengdu and thereby optimizing clinical management, prevention, and control of HIV.

scholarly journals N-Acetylcystein has Potential Effect to Reduce Haematological Abnormalities in HIV/AIDS Patients Undergoing ARV Treatment

2020 ◽  
Vol 10 (4-s) ◽  
pp. 197-200
Author(s):  
Filia Yuniza ◽  
Eddy Mart Salim ◽  
Nova Kurniati ◽  
Harun Hudari ◽  
Erial Bahar ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Potential Effect ◽  
Aids Patients ◽  
Exclusion Criteria ◽  
Double Blind ◽  
Before And After ◽  
The Mean ◽  
Hematological Abnormalities ◽  
Hiv Aids

Aims: to determine the effect of NAC administration on hematological abnormalities in HIV/AIDS patients who are undergoing ARV treatment. Method: This was a pilot study using a double blind randomized clinical trial. A total of 32 subjects who met the inclusion and exclusion criteria were divided into 2 groups, namely placebo and NAC. Subjects in the NAC group were given NAC at a dose of 3x200 mg/day, while the placebo group was given lactose at a dose of 3x200 mg/day. Each group was given treatment for 12 weeks. Before and after treatment, subjects were examined for hematologic parameters. Results:  Most of subjects had normal hematological features. NAC administration did not have a significant effect on the mean levels of Hb, Ht, number of erythrocytes, leukocytes and platelets (p> 0.05). However, NAC administration can reduce the degree of anemia and improve the condition of thrombocytopenia, leukopenia and lymphopenia. Conclusion: NAC administration can reduce hematological abnormalities HIV/AIDS patients undergoing ARV treatment. Keywords: ARV, Hematological abnormalities, HIV/AIDS, NAC.

scholarly journals Seasonal profile and level of CD4+ lymphocytes in the occurrence of cryptosporidiosis and cystoisosporidiosis in HIV/AIDS patients in the Triângulo Mineiro region, Brazil

2007 ◽  
Vol 40 (5) ◽  
pp. 512-515 ◽  
Author(s):  
Márcia Benedita de Oliveira-Silva ◽  
Leonardo Rodrigues de Oliveira ◽  
Júlio César Possati Resende ◽  
Bethânea Crema Peghini ◽  
Luiz Eduardo Ramirez ◽  
...  
Keyword(s):  
Seasonal Pattern ◽  
Aids Patients ◽  
Immunological Status ◽  
Faecal Samples ◽  
Cd4 Lymphocyte ◽  
The Individual ◽  
Cd4 Lymphocytes ◽  
Hiv Aids

Patients with AIDS are particularly susceptible to infection with intestinal coccidia. In this study the prevalence of infections with Cryptosporidium sp and Cystoisospora belli were evaluated among HIV/AIDS patients in the Triângulo Mineiro region, Brazil. Between July 1993 and June 2003 faecal samples from 359 patients were collected and stained by a modified Ziehl-Neelsen method, resulting in 19.7% of positivity for coccidian (8.6% with Cryptosporidium sp, 10.3% with Cystoisospora belli and 0.8% with both coccidian). Patients with diarrhoea and T CD4+ lymphocyte levels < 200 cells/mm3 presented higher frequency of these protozoans, demonstrating the opportunistic profile of these infections and its relationship with the immunological status of the individual. It was not possible to determine the influence of HAART, since only 8.5% of the patients positive for coccidian received this therapy regularly. Parasitism by Cryptosporidium sp was more frequent between December and February and thus was characterised by a seasonal pattern of infection, which was not observed with Cystoisospora belli.

scholarly journals Prevalence of HIV-1 Drug Resistance, Distribution of Subtypes and Drug resistance-associated mutations among Treatment-experienced Individuals in Chengdu, Southwest China, 2014-2016

2019 ◽  
Author(s):  
Jiayi Chen ◽  
Yang Liu ◽  
Sijing Liu ◽  
Dan Yuan ◽  
Ling Su ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Immune Cell ◽  
Capital City ◽  
Epidemiological Surveillance ◽  
Aids Patients ◽  
Viral Loads ◽  
National Capital ◽  
And Control ◽  
Hiv 1 ◽  
Hiv Aids

Abstract Background: The National Free Antiretroviral therapy (ART) Program in China has initiated to provide ART to HIV-1 patients, which may cause problems with drug resistance (DR). The number of HIV/AIDS patients in Chengdu ranks first in the national capital city. However, there is little data on the prevalence of HIV-1 DR in this region. Therefore, epidemiological surveillance was conducted on HIV-1 DR among patients receiving ART in Chengdu. Methods: From 2014 to 2016, HIV/AIDS patients (15 years and older) who had received first-line ART for at least six months were enrolled in this study. Demographic, behavioral information and medical history were recorded, and blood samples were collected for viral loads and immune cell count analyses. HIV-1 pol was amplified, sequenced, and analyzed for HIV-1 subtypes and drug resistance-associated mutations (DRMs). Results: A total of 13,782 individuals were enrolled and 653 cases were considered treatment failure after 6 months of ART. 481 (481/653) samples were amplified and sequenced successfully for subtypes and drug resistance analysis. Six subtypes were identified, among which CRF01_AE (54.3%) and CRF07_BC (41.6%) were the dominant subtypes, and CRF55_01B was detected in Chengdu for the first time. The overall prevalence of HIV-1 DR was 1.8%, with 1.2% to nucleoside reverse transcriptase inhibitors (NRTIs), 1.7% to non-NRTIs (NNRTIs) and 0.14% to protease inhibitors (PIs). The leading DRMs observed in the study were M184I/V (59.59%) against NRTIs and K103N (37.55%) against NNRTIs. Conclusions: This study focused on the HIV-1 molecular surveillance among treatment-experienced individuals in Chengdu. The overall prevalence of DR was relatively low among treated patients. These findings were believed to be contributed to an understanding of HIV-1 subtypes, DR prevalence and DRMs profiles in Chengdu, and thereby optimizing clinical management, prevention and control of HIV.

scholarly journals Effect of N-Acetylcysteine on IL-10 and Total Lymphocyte Count in HIV Infected Patients Undergoing Antiretroviral Treatment

2021 ◽  
Vol 22 (2) ◽  
pp. 114-118
Author(s):  
Filia Yuniza ◽  
Eddy Mart Salim ◽  
Zen Hafy ◽  
Nova Kurniati ◽  
Harun Hudari ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Antiretroviral Therapy ◽  
Lymphocyte Count ◽  
Antiretroviral Treatment ◽  
Total Lymphocyte Count ◽  
Aids Patients ◽  
Double Blind ◽  
Total Lymphocyte ◽  
Hiv Aids

Objective: To determine NAC oral administration’s effect on changes in IL-10 levels and total lymphocyte count (TLC) in patients with HIV/AIDS in Dr Mohammad Hoesin Hospital, Palembang. Material and Methods: This study was a double-blind, randomized clinical trial. A total of 32 HIV/AIDS patients undergoing ARV treatment were randomly divided into two groups: the placebo and NAC groups. In the placebo group, patients were given capsules containing lactose at a dose of 3x1 capsules/ day, while the NAC group, were given NAC at a dose of 3x200 mg/day. Each group was treated for 12 weeks. Results: NAC administration significantly reduced IL-10 levels P= 0.038 but could not significantly increase TLC after treatment P= 0.376. However, TLC on the NAC group remained higher when compared with TLC on the placebo group. Conclusion: NAC administration significantly reduced levels of IL-10 and increased TLC; therefore, NAC has potential effects of increasing the effectiveness of antiretroviral therapy in HIV/AIDS patients, although it still needs to be studied further. J MEDICINE 2021; 22: 114-118

Developing and establishing an advanced nursing practice for HIV abd AIDS patients.

Pflege ◽  
2002 ◽  
Vol 15 (6) ◽  
pp. 293-299 ◽  
Author(s):  
Rebecca Spirig ◽  
Dunja Nicca ◽  
V. Werder ◽  
J. Voggensperger ◽  
Miriam Unger ◽  
...  
Keyword(s):  
Nursing Practice ◽  
Aids Patients ◽  
Advanced Nursing Practice ◽  
Hiv Aids

Die Entwicklung und Etablierung einer erweiterten und vertieften Pflegepraxis («Advanced Nursing Practice») ist ein wichtiger Schritt in Richtung einer zukunftsorientierten Pflege. An der HIV-Sprechstunde der Medizinischen Universitätspoliklinik des Kantonsspitals Basel, wo akut- und chronischkranke PatientInnen mit HIV/Aids medizinisch und pflegerisch behandelt werden, wurde deshalb ein Aktionsforschungsprojekt in Gang gesetzt mit dem Ziel, PatientInnen kompetentere Dienstleistungen anzubieten. Partizipative Aktionsforschung ist ein Prozess, mit dem gleichzeitig Wissen über ein System generiert und dieses System verändert wird. Im Mittelpunkt des Prozesses steht die kontinuierliche Analyse, Verbesserung und Evaluation der Pflege zugunsten von Patienten und Angehörigen. Eine erweiterte und vertiefte HIV/Aids-Pflegepraxis erfordert solides Grundlagenwissen über die Krankheit und über die aktuelle Behandlung. Patientenpräferenzen, Caring, Erfahrungswissen und Evidenz sind wesentliche konzeptuelle Grundpfeiler. Neben der Aneignung von neuen Kenntnissen spezialisierten sich die Pflegenden in einem von ihnen gewählten Gebiet der HIV/Aids-Pflege, z.B. im Umgang mit Medikamenten und der Bedeutung der Therapietreue, Gesundheitsförderung und Prävention oder im Umgang mit Symptomen, um Beratungen und Schulungen für PatientInnen und Angehörige anzubieten. Mit einer erweiterten und vertieften Pflegepraxis werden Pflegende befähigt, den sich abzeichnenden Veränderungen im Gesundheitswesen zukünftig proaktiv begegnen zu können.

Influence of Gender on Sources of Stress In HIV/AIDS Patients

2012 ◽  
Vol 3 (6) ◽  
pp. 426-428
Author(s):  
T. Jayanthi T. Jayanthi ◽  
◽  
Dr. V. Srikanth Reddy
Keyword(s):  
Aids Patients ◽  
Hiv Aids
Sign in / Sign up

Export Citation Format

Share Document